Drugmakers Say Pacific Trade Agreement to Stifle InvestmentBy and
Pact likely to set off intense lobbying in Washington
Other critics say deal hurts access to drugs in poor nations
The biotechnology industry criticized the deal struck by negotiators for the Trans-Pacific Partnership agreement, saying it would undermine innovation by offering only limited protection of the data that drugmakers keep secret from competitors.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.